Novo Nordisk Revamps Executive Team: New Leadership Roles Set to Drive Global Strategy

Novo Nordisk Revamps Executive Team: New Leadership Roles Set to Drive Global Strategy

(IN BRIEF) Effective 3 April 2025, Novo Nordisk will undergo key changes in its Executive Management. Camilla Sylvest, a long-time leader with 28 years at the company, has decided to step down. In response, Ludovic Helfgott will assume expanded responsibilities for Product & Portfolio Strategy, encompassing commercial strategy, medical affairs, and business development across all therapy areas. Thilde Hummel Bøgebjerg is promoted to Executive Vice President, Quality, IT & Environmental Affairs, while Tania Sabroe takes on Global Communication in addition to her role in People & Organisation. These adjustments are part of a broader restructuring of the executive team, which now features a diversified group of leaders responsible for various key functions within the company.

(PRESS RELEASE) BAGSVÆRD, 3-Apr-2025 — /EuropaWire/ — Novo Nordisk has announced several key changes within its Executive Management team, effective 3 April 2025. After a remarkable 28-year tenure with the company, including seven years as Executive Vice President of Commercial Strategy & Corporate Affairs, Camilla Sylvest has decided to leave Novo Nordisk.

In light of this departure, organizational adjustments have been made:

• Ludovic Helfgott, currently Executive Vice President, Rare Disease, will now take on additional responsibilities for Product & Portfolio Strategy. This expanded role encompasses commercial strategy, medical affairs, and business development across all therapy areas. Since joining Novo Nordisk in 2019, Ludovic has successfully established a strategic Rare Disease portfolio. Prior to his tenure at Novo Nordisk, he led cardiovascular, metabolic, and renal portfolios at AstraZeneca.
• Thilde Hummel Bøgebjerg, who has served as Senior Vice President, Product Supply Emerging Technologies for 18 years, has been promoted to Executive Vice President, Quality, IT & Environmental Affairs. Based in Denmark, Thilde has held multiple leadership roles with growing responsibilities in Product Supply and CMC development.
• Tania Sabroe, currently Executive Vice President of People & Organisation, will expand her portfolio to include Global Communication, in addition to her current duties.

With these changes, Novo Nordisk’s Executive Management team, as of 3 April 2025, will consist of:

• Lars Fruergaard Jørgensen, President and CEO*
• Thilde Hummel Bøgebjerg, EVP, Quality, IT & Environmental Affairs
• Maziar Mike Doustdar, EVP, International Operations
• Ludovic Helfgott, EVP, Product & Portfolio Strategy
• Karsten Munk Knudsen, EVP, Chief Financial Officer*
• Martin Holst Lange, EVP, Development
• Dave Moore, EVP, US Operations
• Tania Sabroe, EVP, People, Organisation and Communication
• Marcus Schindler, EVP, Chief Scientific Officer, Research & Early Development
• Henrik Wulff, EVP, Product Supply

*Registered as an executive with the Danish Business Authority.

About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 76,300 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Media Contacts:

SOURCE: Novo Nordisk